Top-News
Finanzdienstleistungen Kanada

Satellos Bioscience News

Aktie
WKN:  A3CSSM ISIN:  CA80401L3083 US-Symbol:  MSCLF
0,305 €
+0,029 €
+10,51%
22:38:54 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
20,65 Mio.
Marktkapitalisierung *
6,14 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 28.09.2021

Satellos Bioscience News

22.03.21 - PR Newswire
IIROC Trading Halt - ICO
IIROC Trading Halt - ICO Canada NewsWire
25.02.21 - PR Newswire
IIROC Trading Resumption - ICO
IIROC Trading Resumption - ICO Canada NewsWire
25.02.21 - PR Newswire
IIROC Trading Halt - ICO
IIROC Trading Halt - ICO Canada NewsWire
13.07.20 - Newsfile
iCo Therapeutics Announces First Quarter 2020 Financial Results
Vancouver, British Columbia--(Newsfile Corp. - July 13, 2020) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the ...
29.05.20 - Newsfile
iCo Therapeutics Inc. Announces Q1 Interim Filing Update
Vancouver, British Columbia--(Newsfile Corp. - May 29, 2020) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") is providing an update on the status of ...
19.05.20 - Newsfile
iCo Therapeutics Announces 2019 Year End Financial Results
Vancouver, British Columbia--(Newsfile Corp. - May 19, 2020) -   iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the year ...
27.04.20 - Newsfile
iCo Therapeutics Inc. Announces Annual Filing Update
Vancouver, British Columbia--(Newsfile Corp. - April 27, 2020) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") is providing an update on the status of ...
15.04.20 - Newsfile
iCo Therapeutics Inc. Announces Oral Amphotericin B (iCo 019) Update / Appointment of Kishor Wasan as Director of Research
Vancouver, British Columbia--(Newsfile Corp. - April 15, 2020) -  iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company") announced today the successful ...
09.03.20 - Newsfile
iCo Therapeutics Announces Leadership Changes
Vancouver, British Columbia--(Newsfile Corp. - March 9, 2020) - iCo Therapeutics Inc.  (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company") announces that Andrew Rae, MBA, has ...
25.02.20 - Newsfile
iCo Therapeutics Successfully Concludes Phase 1b Clinical Study Announces Positive Primary End Point for Oral Amphotericin B
Vancouver, British Columbia--(Newsfile Corp. - February 25, 2020) - iCo Therapeutics Inc.  (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") and its subsidiary, iCo ...
10.02.20 - Newsfile
iCo Therapeutics Announces Completion of Phase 1b Oral Amphotericin B Study Dosing and Follow Up
Vancouver, British Columbia--(Newsfile Corp. - February 10, 2020) - iCo Therapeutics Inc.  (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") and its subsidiary, iCo ...
19.08.19 - DGAP
iCo Therapeutics Inc. Announces the Issuance of 41,200,000 Units Pursuant to its Non-Brokered Private Placement
DGAP-News: iCo Therapeutics Inc. / Key word(s): Miscellaneous iCo Therapeutics Inc. Announces the Issuance of 41,200,000 Units Pursuant to its Non-​Brokered Private Placement ...
07.08.19 - DGAP
iCo Therapeutics Provides Corporate Update
DGAP-News: iCo Therapeutics Inc. / Key word(s): Miscellaneous iCo Therapeutics Provides Corporate Update 07.08.2019 / 04:47 The issuer is solely responsible for the content of ...
28.06.19 - DGAP
iCo Therapeutics Announces AGM Voting Results
DGAP-News: iCo Therapeutics Inc. / Key word(s): Miscellaneous iCo Therapeutics Announces AGM Voting Results 28.06.2019 / 14:03 The issuer is solely responsible for the ...
30.05.19 - DGAP
iCo Therapeutics Announces First Quarter 2019 Financial Results
DGAP-News: iCo Therapeutics Inc. / Key word(s): Miscellaneous iCo Therapeutics Announces First Quarter 2019 Financial Results 30.05.2019 / 22:41 The issuer is solely ...
01.05.19 - DGAP
iCo Therapeutics Announces 2018 Year End Financial Results
DGAP-News: iCo Therapeutics Inc. / Key word(s): Miscellaneous iCo Therapeutics Announces 2018 Year End Financial Results 01.05.2019 / 00:39 The issuer is solely responsible ...
25.02.19 - DGAP
iCo Therapeutics Inc. Announces the Issuance of 14,400,000 Units Pursuant to its C$1,250,000 Non-Brokered Private Placement
DGAP-News: iCo Therapeutics Inc. / Key word(s): Miscellaneous iCo Therapeutics Inc. Announces the Issuance of 14,400,000 Units Pursuant to its C$1,250,000 Non-​Brokered ...
19.02.19 - DGAP
iCo Therapeutics Inc. Announces Upsizing of Non-Brokered Private Placement to $1,250,000 CDN
DGAP-News: iCo Therapeutics Inc. / Key word(s): Miscellaneous iCo Therapeutics Inc. Announces Upsizing of Non-​Brokered Private Placement to $1,250,000 CDN 19.02.2019 / ...
12.02.19 - DGAP
iCo Therapeutics Inc. Announces the Issuance of 4,000,000 Units Pursuant to its C$750,000 Non-Brokered Private Placement
DGAP-News: iCo Therapeutics Inc. / Key word(s): Miscellaneous iCo Therapeutics Inc. Announces the Issuance of 4,000,000 Units Pursuant to its C$750,000 Non-​Brokered Private ...
01.02.19 - DGAP
iCo Therapeutics Inc. Announces Non-Brokered Private Placement to Raise C$750,000
DGAP-News: iCo Therapeutics Inc. / Key word(s): Miscellaneous iCo Therapeutics Inc. Announces Non-​Brokered Private Placement to Raise C$750,000 01.02.2019 / 02:07 The ...

Newssuche

Videos

newspaper
08:55 Uhr +6,89%
Technical Trading: Rohöl Short Chance
Rohöl Short Typ: Turbo Open End WKN: VD4JF9 Hebel: 13 Laufzeit: OpenEnd Einstieg: Market ... Mehr »